Article info

Download PDFPDF

FRI0227 Sarilumab significantly suppresses circulating biomarkers of bone resorption and cardiovascular risk compared with adalimumab: biomarker analysis from the phase 3 monarch study
Free

Authors

Citation

Gabay C, Msihid J, Paccard C, et al
FRI0227 Sarilumab significantly suppresses circulating biomarkers of bone resorption and cardiovascular risk compared with adalimumab: biomarker analysis from the phase 3 monarch study

Publication history

  • First published June 15, 2017.
Online issue publication 
January 09, 2022

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.